A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Status:
Recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of
venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or
refractory chronic lymphocytic leukemia (CLL).